Table 1.

Summary Characteristics of the 11 Cases of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Treated With Prolonged Nirmatrelvir/Ritonavir

Patient ID	Sex	Age	Comorbidity	CD20 Depletion	Days Infected	Maximum Respiratory Support	Severity	Outcome		Treatment Courses	Final Treatment Course		Lineage
								Clinical	Virological		Paxlovid	Combination
OLOL-001	F	50	Hematological malignancy	Yes	72	Low-flow oxygen	Moderate	Recovered	Clear	3	10 d	Remdesivir 5 d	BQ.1.1.2
BMT-002	F	48	NMDA receptor encephalitis	Yes	76	Noninvasive ventilation	Critical	Recovered	Clear	3	18 d	Immunoglobulin	Unknown
BMT-001	F	48	Rheumatoid arthritis	Yes	103	High-flow oxygen	Severe	Recovered	LTFU	1	10 d	Immunoglobulin	Unknown
GSTT-005	F	77	Hematological malignancy	Yes	76	High-flow oxygen	Severe	Recovered	LTFU	2	10 d	Sotrovimab 1000 mg	BQ.1.1
GSTT-004	F	77	Hematological malignancy	Yes	203	Nonhospitalized	Mild	Recovered	Clear	1	10 d	Sotrovimab 1000 mg	BQ.1.1
GSTT-003	F	77	Hematological malignancy	Yes	101	High-flow oxygen	Severe	Recovered	Clear	2	10 d	Remdesivir 10 d + sotrovimab 1000 mg	BQ.1.1.3
GSTT-002	M	55	Hematological malignancy	Yes	236	Hospitalized, no oxygen	Mild	Recovered	Clear	1	10 d	Nil	BA.2.9
GSTT-001	M	61	Hematological malignancy	Yes	137	Invasive ventilation	Critical	Recovered	Clear	4	10 d	Remdesivir 10 d	BA.2.3
UHW-001	M	74	Hematological malignancy; rheumatoid arthritis	Yes	134	CPAP	Critical	Recovered	Clear	5	10 d	Nil	BA.2
UHW-002	F	80	Hematological malignancy	Yes	138	CPAP	Critical	Recovered	Clear	3	14 d	Nil	BL.1
UHW-003	F	68	Hematological malignancy	Nil	94	Low-flow oxygen	Moderate	Recovered	Clear	2	10 d	Nil	BQ.1.1.8

Abbreviations: CPAP, continuous positive airway pressure; d, days; F, female; LTFU, lost to follow-up; M, male; NMDA, N-methyl-d-aspartate receptor.